Twist Bioscience Corp TWST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience to Present at Upcoming Investor Conferences
Notice of Proposed Derivative Settlement: Twist Bioscience Corporation
Twist Bioscience Launches MRD Express with Rapid Turnaround Time
Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Trading Information
- Previous Close Price
- $105.04
- Day Range
- $102.83–112.19
- 52-Week Range
- $24.44–219.22
- Bid/Ask
- $85.76 / $144.28
- Shares Outstanding
- 68.18M
- Market Cap
- $7.33B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.21
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Twist Bioscience Corp provides customizable solutions across the biological continuum, helping customers read, write and innovate in biology. The core of its business is a proprietary platform that allows it to manufacture synthetic DNA by writing DNA on a silicon chip. The company operates as one reportable and operating segment, through which it develops, manufactures and sells DNA Synthesis and Protein Solutions and NGS Applications products and services. It has presence in Americas, EMEA, and APAC. Majority of revenue comes from Americas. Its products are Genes, Oligo Pools, NGS, Variant Libraries, Synthetic Controls, Antibody Discovery, and VDR Solutions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 979
Valuation
Metric | TWST |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.33 |
Price/Sales | 15.21 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | TWST |
|---|---|
Quick Ratio | 5.37 |
Current Ratio | 5.86 |
Interest Coverage | — |
Quick Ratio
TWST
Profitability
Metric | TWST |
|---|---|
Return on Assets (Normalized) | −9.71% |
Return on Equity (Normalized) | −13.40% |
Return on Invested Capital (Normalized) | −12.50% |
Return on Assets
TWST
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|>DjpMN | LOCK|%#XpZ | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%>pdc?N | LOCK|>WG<! | $99B | |||
| Moderna Inc MRNA | LOCK|jTpntCK | LOCK|%mj | $87B | |||
| argenx SE ADR ARGX | LOCK|V!gKGJJ | LOCK|b@ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#QT^WC! | LOCK|&< | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|>N&rZZ?! | LOCK|kM<z | $31B | |||
| Incyte Corp INCY | LOCK|MpZQks | LOCK|m@ | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|<S!?>P | LOCK|<Nw@S | $21B | |||
| BioNTech SE ADR BNTX | LOCK|>m^S%S& | LOCK|GY | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|%Y>^M? | LOCK|mJ | $15B |